Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

Latest Trials

Systemic therapy trial

PROTAC CLL : A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine...

This Phase I trial is seeking to understand the recommended dose of a targeted therapy (BGB-16673) in people with B-Cell Malignancies

Status : Recruiting

Systemic therapy trial

Lynk 003 : A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib...

This phase III trial is trying to evaluate the safety and effectiveness of a targeted cancer drug, given alone and in combination with another targeted cancer drug or chemotherapy, for the treatment of patients with a colorectal cancer that has spread to other parts of the body

Status : Recruiting

Systemic therapy trial

AtTEnd : Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination...

This phase III trial will evaluate whether it is more or less effective to use an immunotherapy, in combination with chemotherapy, to treat women with advanced or recurrent endometrial cancer

Status : Recruiting

Systemic therapy trial

TRANSFORM-1 : A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In...

This phase III trial is testing the combination of two targeted cancer drugs (Ruxolitinib and Navitoclax) to see if it is better than using one targeted cancer drug (Ruxolitinib) to treat people with myelofibrosis

Status : Recruiting

Systemic therapy trial

BGB-3111-11417-101 : A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417...

This phase I trial is trying to determine the best dosing level of a targeted therapy drug (BGB-11417), and assess its effectiveness both by itself and in combination with another targeted therapy (Zanubrutinib)

Status : Recruiting

Systemic therapy trial

A Phase 1b Open-label Study Investigating the Safety, Tolerability, Pharmacokinetics, and...

This Phase I trial is evaluating how safe and tolerable a combination of targeted therapies (Blinatumomab and AMG 404) is in adults with relapsed or refractory B Cell precursor Acute Lymphoblastic Leukaemia

Status : Recruiting

Systemic therapy trial

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of...

This phase I trial seeks to understand how safe and tolerable an immunotherapy drug (AMG 757) is in people with neuroendocrine prostate cancer

Status : Recruiting

Multiple treatment types

CYTOSHRINK : Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination...

This phase II trial is assessing the effect of adding radiotherapy (stereotactic body radiation therapy - SBRT) to the standard of care treatment immunotherapy (ipilimumab/nivolumab), compared with immunotherapy as a standard alone treatment, in people with metastatic kidney cancer

Status : Recruiting

Systemic therapy trial

DESTINY-CRC02 : A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With...

This phase II trial is trying to understand the safety and effectiveness of targeted therapy drug (trastuzumab deruxtecan) in people with HER2-overexpressing advanced colorectal cancer.

Status : Recruiting

Systemic therapy trial

FIDES-03 : A Phase 1b/2 Study of Derazantinib as Monotherapy and Combination Therapy With...

This Phase I/II trial is trying to understand how effective targeted therapy (derazantinib) is alone, or when combined with immunotherapy (atezolizumab) or chemotherapy (paclitaxel) and another targeted therapy (ramucirumab), compared to the standard of care treatment of paclitaxel and ramucirumab in people with HER2-negative gastric adenocarcinoma

Status : Recruiting

 

Looking for a trial? Use the search functionality to find the trial you are finding.